Objective:This study aimed to develop a core outcome set(COS)for use in future studies of stable angina pectoris(SAP)in traditional Chinese medicine(TCM).Methods:Systematic literature reviews and qualitative interview...Objective:This study aimed to develop a core outcome set(COS)for use in future studies of stable angina pectoris(SAP)in traditional Chinese medicine(TCM).Methods:Systematic literature reviews and qualitative interviews with cardiologists and patients with SAP treated using TCM were conducted to generate a set of outcomes.Outcomes were prioritized by stakeholders via two rounds of an online Delphi survey and face-to-face consensus meetings.Following the final consensus meeting,a final COS was generated.Results:An initial set of 324 outcomes was identified.A preliminary list of 65 outcomes was employed in the Delphi study.In total,223 participants from seven stakeholder groups were invited to score outcomes in the first Delphi round:87 completed round 1 and 47 completed round 2.Thirty-one participants attended the consensus meeting and agreed on a final core set of outcomes comprising six items across four domains:frequency of angina attack,duration of angina attack,Seattle angina questionnaire,total exercise duration in the exercise treadmill test,cardiovascular events,and QT interval on electrocardiography.Conclusions:The COS developed in this study provides the minimum requirements for measurement and reporting in future TCM clinical trials for the treatment of SAP.The employment of this COS may reduce heterogeneity across trials and facilitate evidencebased decision-making for stakeholders.展开更多
Objective:To assess outcome indicators in clinical trials and provide a reference for establishing a core outcome set to treat hyperplasia of mammary gland(HMG)with traditional Chinese medicine(TCM).Methods:Eight onli...Objective:To assess outcome indicators in clinical trials and provide a reference for establishing a core outcome set to treat hyperplasia of mammary gland(HMG)with traditional Chinese medicine(TCM).Methods:Eight online databases were searched from their inception to December 31,2022,to assess outcomes reported in randomized controlled trials(RCTs)of HMG treated with TCM.The quality of the included studies was assessed according to the Cochrane Risk of Bias Assessment Tool.All outcomes were extracted,classified,and described.Results:A total of 8249 articles were initially retrieved.Of these,70 articles were eligible and involved 10618 participants with HMG.A total of 17 outcome indicators with a frequency of 271 times were involved and were collected according to six outcome domains.Conclusions:The core outcomes of RCTs of HMG treated with TCM are large and divergent.There are problems in evaluation standards,primary and secondary outcomes,TCM characteristic indicators,long-term prognosis,and standardization of reporting.It is recommended to strengthen the trial design and actively construct the core outcome sets with TCM characteristics for HMG.展开更多
Objective:This work aimed to present a descriptive analysis of the outcome measures used in clinical trials of traditional Chinese medicine(TCM)for patients with stable angina pectoris,and to provide baseline data for...Objective:This work aimed to present a descriptive analysis of the outcome measures used in clinical trials of traditional Chinese medicine(TCM)for patients with stable angina pectoris,and to provide baseline data for the development of core outcome sets(COSs)for relevant clinical trials.Methods:Medical databases were searched to identify randomized trials of the effects of TCM for the treatment of stable angina pectoris.Outcome measures of each trial were extracted.Descriptive statistics were used to analyze the baseline characteristics of outcomes in clinical trials of TCM.Results:94 randomized trials(with 9,111 participants)involving 79 different outcomes were identified.The mean number of outcomes was 5(1-21 per trial).The 5 most commonly reported outcomes were efficacy rate of electrocardiogram,efficacy rate of angina pectoris,efficacy rate of TCM syndrome,fasting lipid indices,and withdrawal rate of nitroglycerin.Several challenges were identified:(1)significant heterogeneity of outcomes and differences in the technique and timing of the measurement of the same outcome;(2)transformation of continuous data into categorical data and presented as such in>90% of trials;(3)few trials on the outcomes associated with the advantages and characteristics of TCM;and(4)selective reporting of outcomes.Conclusions:The outcomes used are excessively heterogenous,and the choice of some outcomes(timing and techniques)for measurement is confusing or inappropriate.Hence,developing and implementing a COS is necessary for greater consistency.展开更多
[Objective]The aim was to study on effects of additives of traditional Chinese medicines on biochemical indices of blood of Wenchang chickens in Hainan. [Method]About 180 female Wenchang chickens were divided into fiv...[Objective]The aim was to study on effects of additives of traditional Chinese medicines on biochemical indices of blood of Wenchang chickens in Hainan. [Method]About 180 female Wenchang chickens were divided into five groups at random with three repetitions for every group and twelve chickens for a repetition. Group 1 was control group and the chickens were fed with basic forages; the 2nd group was control group of antibiotics and the chickens were fed with basic forages and 600 mg /kg of aureomycin; group 3,4 and 5 contained 0. 1%,0. 2% and 0. 3% of the additives respectively,besides basic forages. Chickens at average weight were chosen six from every group on 35th and 56th days,respectively, to prepare serums for biochemical indices of bloods and analyze effects of additives on the indices. [Result]Serum cholinesterase activity and albu- min content were both improved by 0. 1%,0. 2% and 0. 3% of the additives （ P 〈0. 05） ; activity of alkaline phosphatase was enhanced,and serum cholesterol was lowered both by 0. 2% and 0. 3% of the additives （ P 〈0. 05） . [Conclusion]Additives of traditional Chinese medicines have an ac- tive effect on blood biochemical indices of Wenchang chickens.展开更多
Objective:Based on the data mining method,explore the medication rules of Chinese patent medicines for the treatment of digestive system tumors.Method:Based on the"Chinese Traditional Medicine Prescription Databa...Objective:Based on the data mining method,explore the medication rules of Chinese patent medicines for the treatment of digestive system tumors.Method:Based on the"Chinese Traditional Medicine Prescription Database"in https://db.yaozh.com/,collect Chinese patent medicines for the treatment of digestive system tumors,establish an Excel table,and use the ancient and modern medical case cloud platform(V2.2.1)to perform frequency statistics,association rules,and drugs on the data Clustering and complex network analysis.Results:A total of 36 Chinese patent medicines for the treatment of digestive system tumors were screened.The medicinal properties were mainly warm and cold,the taste was bitter and sweet,and the meridians were mainly liver and spleen meridians.High frequency Chinese medicine include Astragalus,Scutellaria-barbata,Ginseng,Curcuma,Triangle,Atractylodes,Hedyotis diffusa,etc.Correlation analysis obtained 17 drug combinations,High-frequency drug pairs include Scutellaria-barbata-Astragalus,Ginseng-Astragalus,Curcuma-Astragalus,Scutellaria-barbata-Curcuma,etc.Cluster analysis found 3 types of drugs.The core drug network is composed of 27 drugs,and the core compatibility network consists of 3 groups of drugs.Conclusion:The Chinese patent compound medicine for the treatment of digestive system tumors has the characteristics of combining cold and warming,replenishing and reducing treatment,and treating the liver and spleen at the same time.The medicine is mainly used to replenish qi and invigorate the spleen,promote blood circulation and remove blood stasis,and clear away heat and detoxification.Replenish qi,nourish yin,invigorate blood,and detoxify are mainly compatible with each other,reflecting the pathogenesis characteristics of"deficiency,stasis,and toxin"in digestive system tumors.Data mining can provide references for the prescription and compatibility of Chinese patent medicines.展开更多
Objective: To investigate the influence of integrated Chinese and Western medicine treatment on the quality of life and laboratory indicators of patients with novel coronavirus pneumonia (COVID-19). Methods: A prospec...Objective: To investigate the influence of integrated Chinese and Western medicine treatment on the quality of life and laboratory indicators of patients with novel coronavirus pneumonia (COVID-19). Methods: A prospective, self-controlled study was conducted to analyze the changes in corresponding laboratory indicators and quality of life in 75 confirmed COVID-19 patients treated with integrated Chinese and Western medicine in our hospital during the early stage, middle stage, recovery period, and two weeks after discharge. The effectiveness and safety of the treatment regimen were evaluated in conjunction with the time for 2019-nCoV nucleic acid conversion, disease progression, and adverse reactions. Results: The PLT levels in the initial stage were significantly lower than those in the recovery period in 75 patients. The CRP levels in the initial stage were significantly lower than those after discharge for 2 weeks. The TBIL, IBTL, and DHIL levels in the initial stage were significantly lower than those in the middle stage. The K+ levels in the initial stage were significantly lower than those in the recovery period and after discharge for 2 weeks. The LYMGH levels in the initial stage were significantly lower than those in the recovery period and after discharge for 2 weeks. The TP and ALB levels in the initial stage were higher than those in the middle stage and the recovery period. The LDH levels, scores of daily activity limitation, scores of respiratory distress symptoms, scores of psychological emotions, CT imaging scores, and positive rate of nucleic acid were significantly lower than those in the recovery period and after discharge for 2 weeks. The AG, CK, CK-MB, and α-HBDH levels in the initial stage were significantly higher than those in the recovery period. However, the AMY level in the initial stage was significantly lower than that in the recovery period and after discharge for 2 weeks (p Conclusion: Integrated Chinese and Western medicine treatment has a significant impact on laboratory indicators such as PLT, LYMGH, CRP, TBIL, IBTL, DHIL, TP, ALB, K+, AG, LDH, CK, CK-MB, α-HBDH, AMY, CT imaging, and 2019-nCoV nucleic acid in COVID-19 patients. It has good clinical efficacy and safety, and can improve the quality of life of patients.展开更多
Objectives:To provide a theoretical basis for the development of the new products of Poria cocos-Atractylodes macrocephala couplet medicine.Methods:All prescription preparations containing Poria cocos and Atractylodes...Objectives:To provide a theoretical basis for the development of the new products of Poria cocos-Atractylodes macrocephala couplet medicine.Methods:All prescription preparations containing Poria cocos and Atractylodes macrocephala were collected from the Drug Standards of the Ministry of Public Health Drug Standard·Traditional Chinese Medicine Set Prescription Preparation(called Traditional Chinese Medicine Set Prescription Preparation for short).After standardization,the information of each prescription preparation was input into the Chinese Traditional Medicine Inheritance Support Platform(V2.5),and the relevant rules of the software were adopted.Data mining methods were used to analyze the frequency of drugs,main symptoms and diseases in prescriptions,and to analyze the regularity of prescriptions.The prescription rules of top 2 high frequency attending syndromes and diseases were analyzed.Results:There were total of 337 prescription preparations containing couplet medicine of Poria cocos and Atractylodes macrocephala,107 kinds of main symptoms and 66 kinds of diseases.The high frequency syndromes were deficiency of Qi and blood and weakness of spleen and stomach,and the high frequency syndromes were anorexia and irregular menstruation.Conclusion:The couplet medicine of Poria cocos-atractylodes macrocephala prescription is mainly used to treat digestive tract diseases and gynecological diseases;it mostly takes tonifying deficiency efficat.It can treat different diseases being compatible with different medicinal materials.The study can provide theoretical basis for clinical application and new drug development of the couplet medicine of Poria cocos-atractylodes macrocephala.展开更多
OBJECTIVE:To explore the differences in Traditional Chinese Medicine(TCM)diagnosis and treatment rules for coronavirus disease 2019(COVID-19)between Northern and Southern China based on the real-world data from 982 CO...OBJECTIVE:To explore the differences in Traditional Chinese Medicine(TCM)diagnosis and treatment rules for coronavirus disease 2019(COVID-19)between Northern and Southern China based on the real-world data from 982 COVID-19 patients.METHODS:All consecutive cases of COVID-19 admitted to the TCM department of designated COVID-19 hospitals in eight provinces and cities were retrospectively analyzed.Patients were divided into a Northern and a Southern group according to the location of the admitting hospital.The symptoms,syndrome elements,syndrome distribution and herbal treatments were analyzed.The core prescriptions were extracted using the multiscale backbone-based network comparison algorithm(msbNC).RESULTS:The distribution of syndrome elements showed that dampness was common in Northern and Southern China,wind and heat were more often present in the South,while fire toxin and spleen deficiency were more often encountered in the North.The distribution of syndromes showed that the South was dominated by heat dampness accumulating in the lung(55.69%),while the North was dominated by dampness-toxin stagnating in the lung(44.90%).The results of core prescription mining showed that dispelling dampness,dispersing wind,clearing heat and strengthening spleen were the common treatment methods in Northern and Southern China.For mild cases,Jinyinhua(Flos Lonicerae)and Lianqiao(Fructus Forsythiae Suspensae)were often used in the South to clear heat and relieve exterior symptoms,while Chaihu(Radix Bupleuri Chinensis)and Huangqin(Radix Scutellariae Baicalensis)were often used in the North to relieve muscles by expelling heat.For moderate cases,Chaihu(Radix Bupleuri Chinensis),Qinghao(Herba Artemisiae Annuae),and Shigao(Gypsum Fibrosum)were often used to clear heat of Tri-jiao Channel and stomach in the South,while Fuling(Poria),Chenpi(Pericarpium Citri Reticulatae),and Dangshen(Radix Codonopsis)were often used to invigorate spleen and remove dampness in the North.For severe cases,spleen invigoration and dampness removal as well as relaxing the bowels and discharging heat were often used in the North.CONCLUSION:There were certain North-South differences in terms of symptoms,syndrome elements and syndrome distribution of COVID-19,as well as differences in core prescriptions during different periods of the disease.The regional differences in the rules of TCM diagnosis and treatment for COVID-19 should be further considered in the process of optimization and revision of relevant treatment guidance.展开更多
目的分析近五年发表的中医药治疗乳腺增生症(Hyperplasia of mammary glands,HMG)的随机对照试验(Randomized controlled trial,RCT)结局指标,为中医药治疗乳腺增生症的核心指标集的构建奠定基础。方法计算机检索中国知网(CNKI)、万方...目的分析近五年发表的中医药治疗乳腺增生症(Hyperplasia of mammary glands,HMG)的随机对照试验(Randomized controlled trial,RCT)结局指标,为中医药治疗乳腺增生症的核心指标集的构建奠定基础。方法计算机检索中国知网(CNKI)、万方数据知识服务平台(WanFang)、维普网(VIP)、中国生物医学文献服务系统(Sinomed)、Pubmed、Cochrane Library和Web of Science数据库自2019年1月1日—2024年5月20日期间的中医药治疗乳腺增生症的随机对照试验,根据纳入、排除标准筛选文献,统计文献基本信息及结局指标信息。结果共纳入175项RCTs,包含18499例患者。涉及中医病证、症状/体征、影像学检查、理化检测、安全性事件、生活质量、远期预后、经济学评估及其他共9类105种结局指标。使用频次排名前五的结局指标有:症状疗效(90.86%)、总有效率(90.86%)、最大肿块直径(67.43%)、雌二醇(Estradiol,E2)(51.43%)、不良反应(50.86%)。结论目前中医药治疗HMG的RCT结局指标存在指标数量与组合选择差异大、疗效评价标准模糊不统一、结局指标中医特色不足、相同指标测量方式差异大、指标测量时间点不统一、随访及远期预后缺乏关注以及经济学评估缺乏、安全性事件报告不清晰等问题。需要制订更为完善的指标集,明确最核心指标,以提高中医药研究的质量。展开更多
目的分析下肢丹毒(Lower leg erysipelas,LLE)患者不同中医证型与临床指标的相关性,指导临床诊疗。方法收集2009年6月—2023年6月期间首都医科大学附属北京中医医院疮疡血管外科住院的LLE患者137例,调取其电子病历,收集人口学资料、症...目的分析下肢丹毒(Lower leg erysipelas,LLE)患者不同中医证型与临床指标的相关性,指导临床诊疗。方法收集2009年6月—2023年6月期间首都医科大学附属北京中医医院疮疡血管外科住院的LLE患者137例,调取其电子病历,收集人口学资料、症状、实验室检查等数据进行回顾性分析,以证型为分组因素,分为3组,利用t检验、秩和检验或卡方检验对每项指标进行分析,将P<0.05的指标进行多因素logistic回归分析。结果3组不同证型的患者共有12项指标有差异(P<0.05)。血分蕴热证患者的中性粒细胞绝对值(第7天)、谷丙转氨酶(治疗前)较高,对该证型影响显著,差异有统计学意义(P<0.05);热毒壅盛证患者白细胞总数(第7天)、中性粒细胞百分比(第7天)较低,红细胞沉降率(第14天)较低,谷丙转氨酶(治疗前)较高,对该证型影响显著,差异有统计学意义(P<0.05);血分蕴热证患者治疗前皮温评分较高,热毒壅盛组治疗前疼痛评分较高,经络瘀滞证患者治疗前疼痛评分较低,对该证型影响显著,差异有统计学意义(P<0.05)。结论LLE的中医证型与炎症指标和肝功能指标有一定相关性,其中中性粒细胞绝对值、中性粒细胞百分比、白细胞总数、谷丙转氨酶、入院时疼痛评分、皮温评分可作为LLE患者的中医辨证分型的关键指标。展开更多
基金supported by the National Natural Science Foundation of China(No.81473544).
文摘Objective:This study aimed to develop a core outcome set(COS)for use in future studies of stable angina pectoris(SAP)in traditional Chinese medicine(TCM).Methods:Systematic literature reviews and qualitative interviews with cardiologists and patients with SAP treated using TCM were conducted to generate a set of outcomes.Outcomes were prioritized by stakeholders via two rounds of an online Delphi survey and face-to-face consensus meetings.Following the final consensus meeting,a final COS was generated.Results:An initial set of 324 outcomes was identified.A preliminary list of 65 outcomes was employed in the Delphi study.In total,223 participants from seven stakeholder groups were invited to score outcomes in the first Delphi round:87 completed round 1 and 47 completed round 2.Thirty-one participants attended the consensus meeting and agreed on a final core set of outcomes comprising six items across four domains:frequency of angina attack,duration of angina attack,Seattle angina questionnaire,total exercise duration in the exercise treadmill test,cardiovascular events,and QT interval on electrocardiography.Conclusions:The COS developed in this study provides the minimum requirements for measurement and reporting in future TCM clinical trials for the treatment of SAP.The employment of this COS may reduce heterogeneity across trials and facilitate evidencebased decision-making for stakeholders.
基金This study was supported by the National Administration of Traditional Chinese Medicine(SATCM-2015-BZ402).
文摘Objective:To assess outcome indicators in clinical trials and provide a reference for establishing a core outcome set to treat hyperplasia of mammary gland(HMG)with traditional Chinese medicine(TCM).Methods:Eight online databases were searched from their inception to December 31,2022,to assess outcomes reported in randomized controlled trials(RCTs)of HMG treated with TCM.The quality of the included studies was assessed according to the Cochrane Risk of Bias Assessment Tool.All outcomes were extracted,classified,and described.Results:A total of 8249 articles were initially retrieved.Of these,70 articles were eligible and involved 10618 participants with HMG.A total of 17 outcome indicators with a frequency of 271 times were involved and were collected according to six outcome domains.Conclusions:The core outcomes of RCTs of HMG treated with TCM are large and divergent.There are problems in evaluation standards,primary and secondary outcomes,TCM characteristic indicators,long-term prognosis,and standardization of reporting.It is recommended to strengthen the trial design and actively construct the core outcome sets with TCM characteristics for HMG.
基金supported by the National Natural Science Foundation Project of China(81473544)Ministry of Education Program for Innovative Research Team(IRT1276)+2 种基金National key research and development projects of modernization of traditional Chinese medicine(2019YFC1710000,2019YFC1710003)Henan Youth Talent Promotion Project(2020HYTP060)the National Basic Research Program of China(2015CB554401).
文摘Objective:This work aimed to present a descriptive analysis of the outcome measures used in clinical trials of traditional Chinese medicine(TCM)for patients with stable angina pectoris,and to provide baseline data for the development of core outcome sets(COSs)for relevant clinical trials.Methods:Medical databases were searched to identify randomized trials of the effects of TCM for the treatment of stable angina pectoris.Outcome measures of each trial were extracted.Descriptive statistics were used to analyze the baseline characteristics of outcomes in clinical trials of TCM.Results:94 randomized trials(with 9,111 participants)involving 79 different outcomes were identified.The mean number of outcomes was 5(1-21 per trial).The 5 most commonly reported outcomes were efficacy rate of electrocardiogram,efficacy rate of angina pectoris,efficacy rate of TCM syndrome,fasting lipid indices,and withdrawal rate of nitroglycerin.Several challenges were identified:(1)significant heterogeneity of outcomes and differences in the technique and timing of the measurement of the same outcome;(2)transformation of continuous data into categorical data and presented as such in>90% of trials;(3)few trials on the outcomes associated with the advantages and characteristics of TCM;and(4)selective reporting of outcomes.Conclusions:The outcomes used are excessively heterogenous,and the choice of some outcomes(timing and techniques)for measurement is confusing or inappropriate.Hence,developing and implementing a COS is necessary for greater consistency.
文摘[Objective]The aim was to study on effects of additives of traditional Chinese medicines on biochemical indices of blood of Wenchang chickens in Hainan. [Method]About 180 female Wenchang chickens were divided into five groups at random with three repetitions for every group and twelve chickens for a repetition. Group 1 was control group and the chickens were fed with basic forages; the 2nd group was control group of antibiotics and the chickens were fed with basic forages and 600 mg /kg of aureomycin; group 3,4 and 5 contained 0. 1%,0. 2% and 0. 3% of the additives respectively,besides basic forages. Chickens at average weight were chosen six from every group on 35th and 56th days,respectively, to prepare serums for biochemical indices of bloods and analyze effects of additives on the indices. [Result]Serum cholinesterase activity and albu- min content were both improved by 0. 1%,0. 2% and 0. 3% of the additives （ P 〈0. 05） ; activity of alkaline phosphatase was enhanced,and serum cholesterol was lowered both by 0. 2% and 0. 3% of the additives （ P 〈0. 05） . [Conclusion]Additives of traditional Chinese medicines have an ac- tive effect on blood biochemical indices of Wenchang chickens.
基金Beijing Municipal Administration of Traditional Chinese Medicine Project(No.2019-ZX-005)。
文摘Objective:Based on the data mining method,explore the medication rules of Chinese patent medicines for the treatment of digestive system tumors.Method:Based on the"Chinese Traditional Medicine Prescription Database"in https://db.yaozh.com/,collect Chinese patent medicines for the treatment of digestive system tumors,establish an Excel table,and use the ancient and modern medical case cloud platform(V2.2.1)to perform frequency statistics,association rules,and drugs on the data Clustering and complex network analysis.Results:A total of 36 Chinese patent medicines for the treatment of digestive system tumors were screened.The medicinal properties were mainly warm and cold,the taste was bitter and sweet,and the meridians were mainly liver and spleen meridians.High frequency Chinese medicine include Astragalus,Scutellaria-barbata,Ginseng,Curcuma,Triangle,Atractylodes,Hedyotis diffusa,etc.Correlation analysis obtained 17 drug combinations,High-frequency drug pairs include Scutellaria-barbata-Astragalus,Ginseng-Astragalus,Curcuma-Astragalus,Scutellaria-barbata-Curcuma,etc.Cluster analysis found 3 types of drugs.The core drug network is composed of 27 drugs,and the core compatibility network consists of 3 groups of drugs.Conclusion:The Chinese patent compound medicine for the treatment of digestive system tumors has the characteristics of combining cold and warming,replenishing and reducing treatment,and treating the liver and spleen at the same time.The medicine is mainly used to replenish qi and invigorate the spleen,promote blood circulation and remove blood stasis,and clear away heat and detoxification.Replenish qi,nourish yin,invigorate blood,and detoxify are mainly compatible with each other,reflecting the pathogenesis characteristics of"deficiency,stasis,and toxin"in digestive system tumors.Data mining can provide references for the prescription and compatibility of Chinese patent medicines.
文摘Objective: To investigate the influence of integrated Chinese and Western medicine treatment on the quality of life and laboratory indicators of patients with novel coronavirus pneumonia (COVID-19). Methods: A prospective, self-controlled study was conducted to analyze the changes in corresponding laboratory indicators and quality of life in 75 confirmed COVID-19 patients treated with integrated Chinese and Western medicine in our hospital during the early stage, middle stage, recovery period, and two weeks after discharge. The effectiveness and safety of the treatment regimen were evaluated in conjunction with the time for 2019-nCoV nucleic acid conversion, disease progression, and adverse reactions. Results: The PLT levels in the initial stage were significantly lower than those in the recovery period in 75 patients. The CRP levels in the initial stage were significantly lower than those after discharge for 2 weeks. The TBIL, IBTL, and DHIL levels in the initial stage were significantly lower than those in the middle stage. The K+ levels in the initial stage were significantly lower than those in the recovery period and after discharge for 2 weeks. The LYMGH levels in the initial stage were significantly lower than those in the recovery period and after discharge for 2 weeks. The TP and ALB levels in the initial stage were higher than those in the middle stage and the recovery period. The LDH levels, scores of daily activity limitation, scores of respiratory distress symptoms, scores of psychological emotions, CT imaging scores, and positive rate of nucleic acid were significantly lower than those in the recovery period and after discharge for 2 weeks. The AG, CK, CK-MB, and α-HBDH levels in the initial stage were significantly higher than those in the recovery period. However, the AMY level in the initial stage was significantly lower than that in the recovery period and after discharge for 2 weeks (p Conclusion: Integrated Chinese and Western medicine treatment has a significant impact on laboratory indicators such as PLT, LYMGH, CRP, TBIL, IBTL, DHIL, TP, ALB, K+, AG, LDH, CK, CK-MB, α-HBDH, AMY, CT imaging, and 2019-nCoV nucleic acid in COVID-19 patients. It has good clinical efficacy and safety, and can improve the quality of life of patients.
文摘Objectives:To provide a theoretical basis for the development of the new products of Poria cocos-Atractylodes macrocephala couplet medicine.Methods:All prescription preparations containing Poria cocos and Atractylodes macrocephala were collected from the Drug Standards of the Ministry of Public Health Drug Standard·Traditional Chinese Medicine Set Prescription Preparation(called Traditional Chinese Medicine Set Prescription Preparation for short).After standardization,the information of each prescription preparation was input into the Chinese Traditional Medicine Inheritance Support Platform(V2.5),and the relevant rules of the software were adopted.Data mining methods were used to analyze the frequency of drugs,main symptoms and diseases in prescriptions,and to analyze the regularity of prescriptions.The prescription rules of top 2 high frequency attending syndromes and diseases were analyzed.Results:There were total of 337 prescription preparations containing couplet medicine of Poria cocos and Atractylodes macrocephala,107 kinds of main symptoms and 66 kinds of diseases.The high frequency syndromes were deficiency of Qi and blood and weakness of spleen and stomach,and the high frequency syndromes were anorexia and irregular menstruation.Conclusion:The couplet medicine of Poria cocos-atractylodes macrocephala prescription is mainly used to treat digestive tract diseases and gynecological diseases;it mostly takes tonifying deficiency efficat.It can treat different diseases being compatible with different medicinal materials.The study can provide theoretical basis for clinical application and new drug development of the couplet medicine of Poria cocos-atractylodes macrocephala.
基金National Key Research and Development Plan:Study on TCM Syndrome Regularity and Optimization of Coronavirus Disease 2019 Diagnosis and Treatment Plan(No.2021YFC1712901)。
文摘OBJECTIVE:To explore the differences in Traditional Chinese Medicine(TCM)diagnosis and treatment rules for coronavirus disease 2019(COVID-19)between Northern and Southern China based on the real-world data from 982 COVID-19 patients.METHODS:All consecutive cases of COVID-19 admitted to the TCM department of designated COVID-19 hospitals in eight provinces and cities were retrospectively analyzed.Patients were divided into a Northern and a Southern group according to the location of the admitting hospital.The symptoms,syndrome elements,syndrome distribution and herbal treatments were analyzed.The core prescriptions were extracted using the multiscale backbone-based network comparison algorithm(msbNC).RESULTS:The distribution of syndrome elements showed that dampness was common in Northern and Southern China,wind and heat were more often present in the South,while fire toxin and spleen deficiency were more often encountered in the North.The distribution of syndromes showed that the South was dominated by heat dampness accumulating in the lung(55.69%),while the North was dominated by dampness-toxin stagnating in the lung(44.90%).The results of core prescription mining showed that dispelling dampness,dispersing wind,clearing heat and strengthening spleen were the common treatment methods in Northern and Southern China.For mild cases,Jinyinhua(Flos Lonicerae)and Lianqiao(Fructus Forsythiae Suspensae)were often used in the South to clear heat and relieve exterior symptoms,while Chaihu(Radix Bupleuri Chinensis)and Huangqin(Radix Scutellariae Baicalensis)were often used in the North to relieve muscles by expelling heat.For moderate cases,Chaihu(Radix Bupleuri Chinensis),Qinghao(Herba Artemisiae Annuae),and Shigao(Gypsum Fibrosum)were often used to clear heat of Tri-jiao Channel and stomach in the South,while Fuling(Poria),Chenpi(Pericarpium Citri Reticulatae),and Dangshen(Radix Codonopsis)were often used to invigorate spleen and remove dampness in the North.For severe cases,spleen invigoration and dampness removal as well as relaxing the bowels and discharging heat were often used in the North.CONCLUSION:There were certain North-South differences in terms of symptoms,syndrome elements and syndrome distribution of COVID-19,as well as differences in core prescriptions during different periods of the disease.The regional differences in the rules of TCM diagnosis and treatment for COVID-19 should be further considered in the process of optimization and revision of relevant treatment guidance.
文摘目的分析近五年发表的中医药治疗乳腺增生症(Hyperplasia of mammary glands,HMG)的随机对照试验(Randomized controlled trial,RCT)结局指标,为中医药治疗乳腺增生症的核心指标集的构建奠定基础。方法计算机检索中国知网(CNKI)、万方数据知识服务平台(WanFang)、维普网(VIP)、中国生物医学文献服务系统(Sinomed)、Pubmed、Cochrane Library和Web of Science数据库自2019年1月1日—2024年5月20日期间的中医药治疗乳腺增生症的随机对照试验,根据纳入、排除标准筛选文献,统计文献基本信息及结局指标信息。结果共纳入175项RCTs,包含18499例患者。涉及中医病证、症状/体征、影像学检查、理化检测、安全性事件、生活质量、远期预后、经济学评估及其他共9类105种结局指标。使用频次排名前五的结局指标有:症状疗效(90.86%)、总有效率(90.86%)、最大肿块直径(67.43%)、雌二醇(Estradiol,E2)(51.43%)、不良反应(50.86%)。结论目前中医药治疗HMG的RCT结局指标存在指标数量与组合选择差异大、疗效评价标准模糊不统一、结局指标中医特色不足、相同指标测量方式差异大、指标测量时间点不统一、随访及远期预后缺乏关注以及经济学评估缺乏、安全性事件报告不清晰等问题。需要制订更为完善的指标集,明确最核心指标,以提高中医药研究的质量。
文摘目的分析下肢丹毒(Lower leg erysipelas,LLE)患者不同中医证型与临床指标的相关性,指导临床诊疗。方法收集2009年6月—2023年6月期间首都医科大学附属北京中医医院疮疡血管外科住院的LLE患者137例,调取其电子病历,收集人口学资料、症状、实验室检查等数据进行回顾性分析,以证型为分组因素,分为3组,利用t检验、秩和检验或卡方检验对每项指标进行分析,将P<0.05的指标进行多因素logistic回归分析。结果3组不同证型的患者共有12项指标有差异(P<0.05)。血分蕴热证患者的中性粒细胞绝对值(第7天)、谷丙转氨酶(治疗前)较高,对该证型影响显著,差异有统计学意义(P<0.05);热毒壅盛证患者白细胞总数(第7天)、中性粒细胞百分比(第7天)较低,红细胞沉降率(第14天)较低,谷丙转氨酶(治疗前)较高,对该证型影响显著,差异有统计学意义(P<0.05);血分蕴热证患者治疗前皮温评分较高,热毒壅盛组治疗前疼痛评分较高,经络瘀滞证患者治疗前疼痛评分较低,对该证型影响显著,差异有统计学意义(P<0.05)。结论LLE的中医证型与炎症指标和肝功能指标有一定相关性,其中中性粒细胞绝对值、中性粒细胞百分比、白细胞总数、谷丙转氨酶、入院时疼痛评分、皮温评分可作为LLE患者的中医辨证分型的关键指标。
